Can Innovent’s PECONDLE rewrite China’s psoriasis treatment playbook with its IL-23p19 antibody?

Innovent Biologics, Inc., listed on the Hong Kong Stock Exchange under the ticker 01801, has achieved a regulatory first in China’s autoimmune disease treatment landscape. The National Medical Products Administration of China has granted market approval to PECONDLE, also known as picankibart injection, a recombinant anti-IL-23p19 monoclonal antibody developed entirely by the Chinese biopharmaceutical company. This milestone marks the first approval of an IL-23p19 monoclonal antibody independently researched and manufactured by a Chinese enterprise, placing Innovent Biologics in direct competition with multinational pharmaceutical companies already marketing imported psoriasis treatments.

The approval authorizes the use of PECONDLE in adult patients with moderate-to-severe plaque psoriasis who are eligible for systemic therapy. For Innovent Biologics, this regulatory milestone strengthens its position as a homegrown innovator in immunology and broadens its commercial footprint beyond oncology, where it has historically maintained the bulk of its presence.

What makes PECONDLE’s dosing schedule a potential game-changer in chronic psoriasis care

In a market where treatment convenience and compliance significantly influence therapeutic outcomes, PECONDLE’s extended maintenance dosing interval stands out. Unlike several other biologics available in the Chinese market, PECONDLE offers a once-every-12-weeks administration schedule following the induction phase. This is currently the longest approved dosing interval among IL-23p19 inhibitors in China.

This attribute is particularly valuable in the context of managing a chronic, relapsing condition like plaque psoriasis, which often requires lifelong treatment. Patients frequently cite the burden of frequent hospital visits and injection schedules as reasons for discontinuing biologic therapy. Innovent Biologics’ picankibart, through its engineered Fc region that enhances pharmacokinetic stability and half-life, is positioned to address this barrier by offering sustained efficacy with reduced dosing frequency.

As more Chinese patients and healthcare providers prioritize quality-of-life outcomes and convenience in long-term autoimmune care, PECONDLE may become a preferred therapeutic option, especially for working-age populations and those in rural or under-resourced healthcare settings.

How the CLEAR-1 clinical trial validated PECONDLE’s therapeutic promise

The approval of picankibart was based on the pivotal Phase 3 clinical trial, CLEAR-1, which enrolled patients in China diagnosed with moderate-to-severe plaque psoriasis. According to data shared by Innovent Biologics, the trial met its primary and secondary endpoints with a high margin of statistical significance. At week 16, 80.3 percent of patients receiving PECONDLE achieved a 90 percent reduction in the Psoriasis Area and Severity Index, known as PASI 90, while 93.5 percent attained sPGA 0 or 1, indicating clear or almost clear skin.

By week 52, these treatment responses remained stable in both the 100 mg and 200 mg maintenance dosing groups. The biologic also showed robust improvement in hard-to-treat areas such as the scalp, nails, palms, and perineum. Notably, it also contributed to improvements in dermatology-specific quality of life as measured by the DLQI scale, with a significant proportion of patients reaching a score of 0 or 1.

Safety outcomes were favorable. The most commonly reported adverse event was upper respiratory tract infection, in line with the safety profiles of other IL-23p19 inhibitors globally. No new or unexpected safety signals emerged, which further supports PECONDLE’s positioning as a long-term treatment option.

Why Chinese dermatologists are optimistic about PECONDLE’s impact on clinical practice

Professor Shi Yuling, the lead investigator of the CLEAR-1 trial and an expert at Shanghai Skin Disease Hospital, emphasized that psoriasis remains a lifelong disease with considerable physical, psychological, and social burden. While a complete cure remains elusive, treatment goals have evolved toward deep skin clearance and improved quality of life, with PASI 90 or even PASI 100 now considered benchmarks of success.

Professor Shi noted that antibodies targeting the IL-23p19 subunit have shown strong potential for maintaining long-term efficacy and simplifying patient management. She described PECONDLE’s combination of rapid lesion clearance, durable outcomes, and long-interval dosing as a meaningful advancement for dermatology in China, particularly because it reflects domestic biopharma innovation.

How Innovent Biologics is building a broader autoimmune pipeline around picankibart

Dr. Lei Qian, Chief R&D Officer for General Biomedicine at Innovent Biologics, described PECONDLE as the lead asset in the company’s growing autoimmune disease portfolio. In addition to the CLEAR-1 trial, the company is pursuing multiple lifecycle management studies including CLEAR-2 and CLEAR-3, which are evaluating outcomes related to treatment withdrawal, re-initiation, and switching from other biologics.

Clinical development is also expanding into new indications. A Phase 2 study evaluating picankibart in moderately to severely active ulcerative colitis is currently underway, alongside early-stage development for adolescent psoriasis and psoriatic arthritis in adult patients. According to Dr. Qian, the goal is to build robust real-world and trial-based evidence supporting picankibart across multiple inflammatory diseases where IL-23 signaling plays a critical role.

This strategic move positions Innovent Biologics to compete not only in dermatology, but also in the gastrointestinal and rheumatology biologics markets, where imported IL-23 and IL-17 inhibitors have historically dominated.

Why IL-23p19 antibodies are reshaping global psoriasis treatment benchmarks

Over the last five years, IL-23p19 inhibitors have become the biologic class of choice for dermatologists treating moderate-to-severe plaque psoriasis. These agents work by selectively targeting the p19 subunit of interleukin-23, thereby modulating inflammatory pathways implicated in the pathogenesis of psoriasis without interfering with IL-12 mediated immunity.

The result is a favorable balance of efficacy, safety, and durability. Products such as guselkumab and risankizumab have already set high standards in North America and Europe. However, in China, access to these imported therapies has been limited by cost and reimbursement challenges. PECONDLE offers an alternative that is locally developed, potentially more affordable, and optimized for domestic use.

Healthcare analysts believe that Innovent Biologics could carve out a competitive niche in China’s growing psoriasis biologics market, particularly among patients seeking advanced yet accessible therapies. The domestic angle is expected to play well with policy makers and national payors who are incentivizing innovation within the local pharmaceutical ecosystem.

How investors and institutions are reacting to Innovent’s regulatory momentum

Following the announcement of the NMPA approval, shares of Innovent Biologics experienced a modest uptick. While short-term stock movement remained subdued, several institutional analysts interpreted the milestone as an important inflection point for the company’s non-oncology ambitions.

Historically known for its cancer therapies, Innovent has now signaled a credible pivot toward chronic autoimmune conditions. With PECONDLE as a platform anchor, the company is expected to grow its market share in immunology, an area that has traditionally been dominated by multinational pharmaceutical companies.

Investor sentiment appears cautiously bullish. Fund managers focused on China’s healthcare sector are monitoring the pace of PECONDLE’s uptake, reimbursement progress, and longer-term data readouts from the CLEAR-2 and CLEAR-3 trials. The company’s partnership network, which includes global names such as Eli Lilly, Roche, Takeda, and Sanofi, provides additional validation and optionality for international expansion.

What PECONDLE’s approval means for China’s domestic innovation agenda

Beyond Innovent Biologics itself, the approval of PECONDLE represents a broader strategic victory for China’s biopharmaceutical industry. The ability to independently develop and commercialize an advanced biologic in a therapeutic area historically dominated by foreign players aligns with the country’s push for pharmaceutical self-reliance and innovation-driven healthcare.

It also demonstrates the growing scientific and regulatory capabilities within China’s clinical research ecosystem. The successful execution of a pivotal trial, coupled with positive regulatory engagement, reflects a maturation of domestic drug development pipelines that could accelerate future innovation across other disease areas.

As biologics continue to displace older therapies like methotrexate, cyclosporine, and retinoids, local innovation in precision immunology will likely define the next phase of treatment evolution in China. PECONDLE’s approval may be the first of many domestic breakthroughs to come.

What are the key takeaways from Innovent Biologics’ PECONDLE approval for plaque psoriasis?

• Innovent Biologics has received regulatory approval from China’s National Medical Products Administration for PECONDLE, the country’s first domestically developed IL-23p19 monoclonal antibody for treating moderate-to-severe plaque psoriasis in adults.

• PECONDLE, also known as picankibart injection, demonstrated strong efficacy in the CLEAR-1 Phase 3 trial, with over 80 percent of patients achieving PASI 90 at week 16 and maintaining results through week 52.

• The drug offers the longest maintenance dosing interval among IL-23p19 inhibitors in China, requiring administration only once every 12 weeks, which could improve patient compliance and convenience.

• The treatment showed significant improvements in difficult-to-treat areas such as the scalp, nails, and palms, and also delivered improvements in quality-of-life indicators such as DLQI scores.

• Safety data from the clinical trial were favorable, with no new safety signals identified and the most common adverse event being upper respiratory tract infections.

• Innovent Biologics plans to expand the clinical use of picankibart to other autoimmune conditions, including ulcerative colitis and psoriatic arthritis, supported by ongoing trials such as CLEAR-2 and CLEAR-3.

• Analysts believe PECONDLE could help Innovent Biologics capture market share in China’s psoriasis biologics segment, especially due to its domestic development and pricing potential compared to imported therapies.

• The approval of PECONDLE is also seen as a broader victory for China’s domestic biopharmaceutical industry, signaling its ability to develop and commercialize advanced biologics independently.

• Investor sentiment around Innovent Biologics remains cautiously optimistic, with PECONDLE expected to become a platform asset for the company’s autoimmune and immunology strategy.

• The drug’s launch supports China’s pharmaceutical innovation agenda and underscores a shift toward self-sufficiency and homegrown clinical capabilities in high-value biologics.